Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.

Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. Prostate (2014) 1.01

Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy. Oncotarget (2015) 0.91

Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided. Biomed Res Int (2014) 0.90

A circulating miRNA assay as a first-line test for prostate cancer screening. Br J Cancer (2016) 0.78

Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol (2015) 0.77

Strategies for prevention of ultrasound-guided prostate biopsy infections. Infect Drug Resist (2016) 0.75

The characteristics and spatial distributions of initially missed and rebiopsy-detected prostate cancers. Ultrasonography (2016) 0.75

3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy. Exp Ther Med (2014) 0.75

Application of transrectal ultrasound-guided repeat needle biopsy in the diagnosis of prostate cancer in Chinese population: A retrospective study. J Res Med Sci (2016) 0.75

Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. Asian J Androl (2015) 0.75

Clinicopathologic differences between prostate cancers detected during initial and repeat transrectal ultrasound-guided biopsy in Korea. Korean J Urol (2014) 0.75

Diagnostic role of prostate resection in the elderly patients who experience significant co-morbidity with a high clinical suspicion of prostate cancer. J Korean Med Sci (2013) 0.75

Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92

Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77

Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res (2010) 2.50

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48

Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41

Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37

Regional copy number-independent deregulation of transcription in cancer. Nat Genet (2006) 2.33

Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30

Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26

Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int (2012) 2.20

Multi-institutional study of symptomatic deep venous thrombosis and pulmonary embolism in prostate cancer patients undergoing laparoscopic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2007) 2.19

Evaluation of combined oncological and functional outcomes after radical prostatectomy: trifecta rate of achieving continence, potency and cancer control--a literature review. Urology (2010) 2.19

Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15

Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol (2007) 2.10

Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09

SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03

Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med (2010) 1.92

Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87

Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83

Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol (2009) 1.79

A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77

Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73

Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? J Urol (2009) 1.73

Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68

Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68

Oncologic outcome after extraperitoneal laparoscopic radical prostatectomy: midterm follow-up of 1115 procedures. Eur Urol (2009) 1.63

Modified supine percutaneous nephrolithotomy for large kidney and ureteral stones: technique and results. Eur Urol (2011) 1.58

External validation of the updated partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys (2008) 1.58

The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol (2009) 1.54

Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res (2003) 1.52

Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol (2013) 1.51

The risk of upstaged disease increases with body mass index in low-risk prostate cancer patients eligible for active surveillance. Eur Urol (2011) 1.50

Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate (2011) 1.49

Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem (2006) 1.47

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy? Urology (2013) 1.45

Oncologic outcomes and survival in pT0 tumors after radical cystectomy in patients without neoadjuvant chemotherapy: results from a large multicentre collaborative study. Ann Surg Oncol (2011) 1.42

Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42

International Prostate Symptom Score is a predictive factor of lower urinary tract symptoms after radical prostatectomy. Int J Urol (2015) 1.41

Oncogene-mediated alterations in chromatin conformation. Proc Natl Acad Sci U S A (2012) 1.40

Sexual dysfunction is common and overlooked in female patients with hypertension. J Sex Marital Ther (2002) 1.40

Surgical management of BPH in patients on oral anticoagulation: transurethral bipolar plasma vaporization in saline versus transurethral monopolar resection of the prostate. Can J Urol (2011) 1.38

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol (2011) 1.36

Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery (2006) 1.33

The learning curve for laparoscopic radical prostatectomy: an international multicenter study. J Urol (2010) 1.30

Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology (2003) 1.28

Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol (2006) 1.27